1. Home
  2. TFSL vs ERAS Comparison

TFSL vs ERAS Comparison

Compare TFSL & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TFS Financial Corporation

TFSL

TFS Financial Corporation

HOLD

Current Price

$18.21

Market Cap

4.7B

Sector

Finance

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$17.72

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TFSL
ERAS
Founded
1938
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7B
4.0B
IPO Year
2006
2021

Fundamental Metrics

Financial Performance
Metric
TFSL
ERAS
Price
$18.21
$17.72
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$14.25
AVG Volume (30 Days)
717.6K
4.7M
Earning Date
05-12-2026
05-08-2026
Dividend Yield
7.68%
N/A
EPS Growth
14.29
36.23
EPS
0.16
N/A
Revenue
N/A
N/A
Revenue This Year
$9.16
N/A
Revenue Next Year
$5.22
N/A
P/E Ratio
$115.47
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.54
$1.33
52 Week High
$18.53
$24.28

Technical Indicators

Market Signals
Indicator
TFSL
ERAS
Relative Strength Index (RSI) 65.66 48.36
Support Level $13.21 $12.36
Resistance Level $18.53 $18.20
Average True Range (ATR) 0.28 1.24
MACD -0.03 -0.36
Stochastic Oscillator 86.96 7.23

Price Performance

Historical Comparison
TFSL
ERAS

About TFSL TFS Financial Corporation

TFS Financial Corp is the holding company for the Third Federal Savings and Loan Association of Cleveland. The company's ownership in the savings and loan association is its primary business activity. The association's principal business consists of originating and servicing residential real estate mortgage loans and attracting retail savings deposits. It does so by offering products with competitive rates and yields. The company also operates Third Capital, a wholly owned subsidiary that serves as a holding company or as an investor in vehicles such as private equity funds. Third Capital has interests in lease transactions of commercial buildings, title agencies providing escrow and settlement services, and reinsurance of private mortgage insurance on residential loans.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: